AZD0240

AZD0240 is a CRISPR-engineered autologous TCR-T cell therapy that targets the KRAS G12D mutation presented by HLA-A*11:01 or HLA-A*11:02 molecules. It employs a novel multi-armoring strategy to improve epitope sensitivity and reduce off-target reactivity, aiming to expand the therapeutic window and safety profile. AZD0240 is being developed for the treatment of advanced solid tumors, including colorectal cancer, pancreatic cancer, non-small cell lung cancer, and other neoplasms with KRAS G12D mutations. It is in early clinical development, with the first-in-human trials sponsored by AstraZeneca and its subsidiary Neogene Therapeutics. The therapy is a key part of emerging targeted immunotherapy approaches seeking to address oncogenic KRAS mutations in solid tumors[1][2][3][4][6][7].